Stock LRMR LARIMAR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Larimar Therapeutics, Inc.

Equities

LRMR

US5171251003

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
6.44 USD +1.74% Intraday chart for Larimar Therapeutics, Inc. -1.38% +41.54%
Mar. 19 North American Morning Briefing : Stock Futures -2- DJ
Mar. 14 Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on Larimar Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3ac97a369f4ff3c6586.crsskyAZz8jhh_5OqJO1p-KM9v609vTfC9lFSjHvg7U.Qf0c2G5tpqSm4p0l_tLA3oXav8b9rKSQUZ4aOHOE08cw1k3BR1bioLXDiQ~946145c5adc80870f4365e2fd2e263d4

Analyst Recommendations on Larimar Therapeutics, Inc.

Guggenheim Adjusts Price Target on Larimar Therapeutics to $25 From $14, Maintains Buy Rating MT
Citigroup Adjusts Price Target on Larimar Therapeutics to $10 From $4.50, Maintains Buy Rating MT
JMP Securities Adjusts Price Target on Larimar Therapeutics to $25 From $17, Maintains Market Outperform Rating MT
Citigroup Upgrades Larimar Therapeutics to Buy From Neutral, Price Target is $4.50 MT
Citigroup Cuts Larimar Therapeutics' Price Target to $4.50 From $7, Maintains Neutral Rating MT
Guggenheim Adjusts Larimar Therapeutics' Price Target to $14 From $12, Keeps Buy Rating MT
Citigroup Initiates Larimar Therapeutics at Neutral Rating MT
Guggenheim Starts Larimar Therapeutics at Buy With $12 Price Target MT
JMP Securities Adjusts Larimar Therapeutics' Price Target to $16 from $10, Maintains Market Outperform Rating MT
William Blair Upgrades Larimar Therapeutics to Outperform From Market Perform MT
JMP Securities Adjusts Larimar Therapeutics' Price Target to $8 From $30, Maintains Market Outperform Rating MT
William Blair Downgrades Larimar Therapeutics to Market Perform From Outperform MT
LARIMAR THERAPEUTICS : JMP Securities Adjusts Price Target on Larimar Therapeutics to $30 From $43, Maintains Market Outperform Rating MT
LARIMAR THERAPEUTICS : JMP Securities Starts Larimar Therapeutics at Market Outperform with $35 Price Target MT
LARIMAR THERAPEUTICS : William Blair Initiates Coverage on Larimar Therapeutics With Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
6.44 USD
Average target price
19.86 USD
Spread / Average Target
+208.46%
High Price Target
27 USD
Spread / Highest target
+319.25%
Low Price Target
7.19 USD
Spread / Lowest Target
+11.65%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Larimar Therapeutics, Inc.

Guggenheim
Citigroup
JMP Securities
William Blair & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LRMR Stock
  4. Consensus Larimar Therapeutics, Inc.